U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Go back to U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer| Gilead Sciences (NASDAQ: GILD) | Delayed: 130.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.34 | 52 Week High | $108.63 | |||
| Open | $130.34 | 52 Week Low | $71.39 | |||
| Day High | $130.34 | P/E | 72.01 | |||
| Day Low | $130.34 | EPS | $1.81 | |||
| Volume | 2,993 | |||||
